Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ADVERUM BIOTECHN RG (NQ: ADVM)
6.300 USD  -0.150 (-2.33%)
Official Closing Price  /  Updated: 8:00 PM EDT, Apr 20, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 316,025
Open 6.500
Bid (Size) 6.200 (1700)
Ask (Size) 6.750 (500)
Prev. Close 6.450
Today's Range 6.200 - 6.500
52wk Range 2.400 - 8.590
Shares Outstanding 62,224,609
Dividend Yield N/A
Performance
YTD
+72.60%
+72.60%
1 Month
-1.56%
-1.56%
3 Month
+22.33%
+22.33%
6 Month
+88.06%
+88.06%
1 Year
+133.33%
+133.33%
Top News
More News
Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Teck Resources Ltd... Read More
from GlobeNewswire News Releases
Research Report Identifies Pan American Silver, Ballard Power, Silvercorp Metals, SunOpta, Baidu, and Adverum Biotechnologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pan American Silver Corp.... Read More
from GlobeNewswire News Releases
More News
Read More
Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies
from PR Newswire
Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
Adverum Biotechnologies to Present at Upcoming Investor Conferences
from GlobeNewswire News Releases
Adverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 Gene Therapy for A1AT Deficiency
from GlobeNewswire News Releases
Adverum Biotechnologies Announces Closing of $69 Million Public Offering
from GlobeNewswire News Releases
Adverum Biotechnologies Announces Pricing of $60 Million Public Offering of Common Stock
from GlobeNewswire News Releases
Adverum Biotechnologies Announces Proposed Public Offering of Common Stock
from GlobeNewswire News Releases
Adverum Biotechnologies Enters Oversold Territory (ADVM)
category Stocks
from Market News Video
BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32
category companyNews
from Reuters: Company News
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial